Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1339-1346

  Paul, Gesine ^a   Zachrisson, Olof ^b   Varrone, Andrea ^c   Almqvist, Per ^b,d   Jerling, Markus ^b   Lind, Göran ^d   Rehncrona, Stig ^e   Linderoth, Bengt ^d   Bjartmarz, Hjalmar ^e   Shafer, Lisa L ^f   Coffey, Robert ^f   Svensson, Mikael ^d   Mercer, Katarina Jansson ^b   Forsberg, Anton ^c   Halldin, Christer ^c   Svenningsson, Per ^d   Widner, Håkan ^a   Frisén, Jonas ^c   Pålhagen, Sven ^d   Haegerstrand, Anders ^b  

^a LUND UNIVERSITY   (Sweden)

^b NeuroNova AB   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; ANTIPARKINSON AGENT; DOPAMINE TRANSPORTER; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; PROTEIN BINDING;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRADYKINESIA; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART VENTRICLE WALL; HUMAN; IMPLANTABLE PUMP; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STEM CELL; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ACUITY; AGED; CLINICAL TRIAL; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MULTICENTER STUDY; PUTAMEN; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-SIS; PUTAMEN; TREATMENT OUTCOME;

EID: 84924033997     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79635     Document Type: Article

References (19)

1. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010;184:237-264.
2. Hickey P, Stacy M. AAV2-neurturin (CERE-120) for Parkinson's disease. Expert Opin Biol Ther. 2013;13(1):137-145.
3. Nutt JG, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73.
4. Aviles-Olmos I, et al. Exenatide a nd the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123(6):2730-2736.
5. Nikkhah G, et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res. 1993;92(3):516-523.
6. Othberg A, Odin P, Ballagi A, Ahgren A, Funa K, Lindvall O. Specific effects of platelet derived growth factor (PDGF) o n fetal rat and human dopaminergic neurons in vitro. Exp Brain Res. 1995;105(1):111-122.
7. Pietz K, Odin P, Funa K, Lindvall O. Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. Neurosci Lett. 1996;204(1):101-104.
8. Funa K, et al. Enhanced synthesis of plateletderived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience. 1996;74(3):825-833.
9. Zachrisson O, et al. Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis. 2011;1(1):49-63.
10. Goetz CG, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008;23(5):700-707.
11. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease f ollows a single exponential rather than linear decline. J Nucl Med. 2004;45(10):1694-1697.
12. Halldin C, et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220-1230.
13. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantificat ion using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36(10):1639-1650.
14. Schain M, et al. Quantification of serotonin transporter availability with [11C]MADAM-A comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60(1):800-807.
15. Cselenyi Z, Olsson H, Farde L, Gulyas B. Wavelet-Aided parametric mapping of cerebral dopamine D2 recepto rs using the high affinity PET radioligand [11C]FLB 457. Neuroimage. 2002;17(1):47-60.
16. Brownell AL, Jenkins BG, Isacson O. Dopamine imaging markers and predictive mathematical models for progress ive degeneration in Parkinson's disease. Biomed Pharmacother. 1999;53(3):131-140.
17. Hilker R, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographi c imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378-382.
18. Nandhagopal R, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009;132(pt 11):2970-2979.
19. Kuriakose R, Stoessl AJ. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog Brain Res. 2010;184:177-192.